The London-listed stock trading under the ticker LSE:IBAI is one of the market's smallest and most thinly traded healthcare names, and on 5-6 August 2026 it earned a place on London South East's "All-Share Fallers" list. According to that data, the shares closed at …
Shares in the AIM-listed clinical-stage group ended Wednesday 5 August 2026 at 8.00p, a rise of 1.10p, or 15.28%, on the day, according to London South East's All-Share risers list. It was one of the steeper single-session gains on the junior market, and it …
LSE:CRTXgained5.26% on 6 August 2026as buying interest returned to the healthcare sector, with investors focusing on companies approaching important clinical development milestones.
LSE:VALadvanced4.91% on 6 August 2026as investors returned to selected biotechnology companies with differentiated oncology development strategies and multiple potential commercial catalysts.
LSE:ABDXadvanced4.67% on 6 August 2026as investors showed renewed interest in healthcare technology companies benefiting from increasing demand for rapid diagnostic solutions and contract development services.
Futura Medical plc attracted renewed buying interest during Thursday's trading session afterLSE:FUM advanced 5.54%, outperforming many healthcare peers on the UK market.
Reports of a tie-up between Britain's most valuable company and its US rival remain unconfirmed by either side, with no deal terms in existence. The "$400bn" is combined market value, not a transaction price, and scepticism is warranted.
A Financial Times report of preliminary AstraZeneca–Bristol Myers Squibb talks — unconfirmed by either company — knocked up to 9% off AstraZeneca's shares. Note the headline's "£400bn" is a sterling overstatement: the combined value is roughly $400bn, about £315bn.
Shield Therapeutics Plc is a commercial-stage pharmaceutical company focused on the treatment of iron deficiency through its flagship therapy,ACCRUFeR®(ferric maltol). The company markets its treatment across multiple international markets while pursuing additional regulatory approvals, label expansions, and commercial partnerships to broaden its global reach.
Renalytix Plc is a precision medicine company specializing in artificial intelligence-enabled diagnostics for chronic kidney disease. Its flagship product,KidneyIntelX.dkd, is an FDA-authorized prognostic test designed to identify patients at elevated risk of kidney disease progression, enabling earlier clinical intervention and improved patient outcomes.